Tandem Diabetes Care (TNDM) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

TNDM Stock Forecast


Tandem Diabetes Care (TNDM) stock forecast, based on 39 Wall Street analysts, predicts a 12-month average price target of $25.56, with a high of $35.00 and a low of $20.00. This represents a 34.95% increase from the last price of $18.94.

$15 $23 $31 $39 $47 $55 High: $35 Avg: $25.56 Low: $20 Last Closed Price: $18.94

TNDM Stock Rating


Tandem Diabetes Care stock's rating consensus is Buy, based on 39 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 21 Buy (53.85%), 17 Hold (43.59%), 1 Sell (2.56%), and 0 Strong Sell (0.00%).

Buy
Total 39 1 17 21 Strong Sell Sell Hold Buy Strong Buy

TNDM Price Target Upside V Benchmarks


TypeNameUpside
StockTandem Diabetes Care34.95%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks20.73%

Price Target Trends


1M3M12M
# Anlaysts1815
Avg Price Target$20.00$26.00$25.60
Last Closing Price$18.94$18.94$18.94
Upside/Downside5.60%37.28%35.16%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 262713-123
Jan, 262713-123
Dec, 252614-123
Nov, 253614-124
Oct, 253613-123
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 04, 2026Stifel Nicolaus$20.00$19.114.66%5.60%
Jan 09, 2026David RomanGoldman Sachs$25.00$22.5011.11%32.00%
Dec 18, 2025Truist Financial$24.00$22.228.01%26.72%
Dec 17, 2025RBC Capital$30.00$22.8131.52%58.39%
Dec 17, 2025William PlovanicCanaccord Genuity$35.00$22.6054.87%84.79%
Dec 17, 2025Anthony PetroneMizuho Securities$21.00$22.60-7.08%10.88%
Dec 16, 2025Robert W. Baird$30.00$22.1235.62%58.39%
Dec 02, 2025Morgan Stanley$23.00$20.5112.14%21.44%
Oct 15, 2025Richard NewitterTruist Financial$16.00$15.115.89%-15.52%
Sep 08, 2025Suraj KaliaOppenheimer$22.00$12.5076.00%16.16%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Jan 09, 2026BernsteinMarket PerformMarket Performhold
Jan 09, 2026Goldman SachsNeutralNeutralhold
Dec 17, 2025RBC CapitalOutperformOutperformhold
Dec 11, 2025CitigroupNeutralNeutralhold
Oct 07, 2025CitigroupNeutralNeutralhold
Aug 12, 2025CitigroupNeutralNeutralupgrade
Aug 11, 2025Lake StreetBuyHolddowngrade
Aug 07, 2025Piper SandlerOverweightNeutraldowngrade
May 22, 2025CitigroupNeutralNeutralhold
Jan 08, 2025BernsteinOutperformOutperformhold

Financial Forecast


EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.25$-1.47$-3.43$-1.47----
Avg Forecast$0.30$-1.09$-3.21$-1.69$-1.22$-0.76$-0.27$-0.07
High Forecast$0.32$-1.07$-2.99$-1.35$-0.78$-0.19$0.34$-0.06
Low Forecast$0.30$-1.13$-3.39$-1.77$-1.43$-1.08$-0.66$-0.07
Surprise %-16.67%34.86%6.85%-13.02%----

Revenue Forecast

$650M $800M $950M $1B $1B $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$702.80M$801.22M$747.72M$940.20M----
Avg Forecast$691.83M$802.00M$764.45M$909.25M$1.01B$1.13B$1.25B$1.37B
High Forecast$726.08M$823.70M$768.90M$935.20M$1.03B$1.13B$1.27B$1.40B
Low Forecast$678.59M$790.66M$755.55M$902.72M$999.97M$1.12B$1.23B$1.34B
Surprise %1.59%-0.10%-2.19%3.40%----

Net Income Forecast

$-350M $-270M $-190M $-110M $-30M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$15.57M$-94.59M$-222.61M$-96.03M----
Avg Forecast$20.84M$21.80M$-222.61M$-101.26M$-78.17M$-44.51M$-14.71M$-4.22M
High Forecast$27.73M$29.60M$-135.07M$-87.83M$-50.98M$-12.35M$22.31M$-4.13M
Low Forecast$13.95M$13.99M$-310.15M$-114.70M$-92.69M$-70.45M$-43.04M$-4.35M
Surprise %-25.30%-533.97%--5.17%----

TNDM Forecast FAQ


Is Tandem Diabetes Care stock a buy?

Tandem Diabetes Care stock has a consensus rating of Buy, based on 39 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 21 Buy, 17 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Tandem Diabetes Care is a favorable investment for most analysts.

What is Tandem Diabetes Care's price target?

Tandem Diabetes Care's price target, set by 39 Wall Street analysts, averages $25.56 over the next 12 months. The price target range spans from $20 at the low end to $35 at the high end, suggesting a potential 34.95% change from the previous closing price of $18.94.

How does Tandem Diabetes Care stock forecast compare to its benchmarks?

Tandem Diabetes Care's stock forecast shows a 34.95% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (20.73%).

What is the breakdown of analyst ratings for Tandem Diabetes Care over the past three months?

  • February 2026: 8.70% Strong Buy, 30.43% Buy, 56.52% Hold, 0% Sell, 4.35% Strong Sell.
  • January 2026: 8.70% Strong Buy, 30.43% Buy, 56.52% Hold, 0% Sell, 4.35% Strong Sell.
  • December 2025: 8.70% Strong Buy, 26.09% Buy, 60.87% Hold, 0% Sell, 4.35% Strong Sell.

What is Tandem Diabetes Care’s EPS forecast?

Tandem Diabetes Care's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.22, marking a -17.01% decrease from the reported $-1.47 in 2024. Estimates for the following years are $-0.76 in 2026, $-0.27 in 2027, and $-0.07 in 2028.

What is Tandem Diabetes Care’s revenue forecast?

Tandem Diabetes Care's average annual revenue forecast for its fiscal year ending in December 2025 is $1.01B, reflecting a 7.58% increase from the reported $940.2M in 2024. The forecast for 2026 is $1.13B, followed by $1.25B for 2027, and $1.37B for 2028.

What is Tandem Diabetes Care’s net income forecast?

Tandem Diabetes Care's net income forecast for the fiscal year ending in December 2025 stands at $-78.171M, representing a -18.59% decrease from the reported $-96.025M in 2024. Projections indicate $-44.508M in 2026, $-14.707M in 2027, and $-4.223M in 2028.